Jump to content

Property:Specifications on cancer therapies

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
S
Radiation treatment of patients with inoperable abdominal cancer or postoperative radiotherapy of abdominal cancer due to lymph node involvement.  +
Breast cancer survivors; completed primary treatment(s) for invasive, early stage breast cancer at least 12 months prior and no more than 10 years prior; received chemotherapy (neo-adjuvant or adjuvant with any medically-prescribed agent/regime) for treatment  +
Chemptherapy/Radiation therapy/OP (at least 6 weeks before or after surgery)  +
Chemotherapy patients (received chemotherapy in the 4 weeks before baseline and who intended to continue chemotherapy during the study), per arm: THC = 52% Cannabis extract = 47% Placebo = 52%  +
Of the 58 patients, 41% underwent primary surgical resection with adjuvant radiotherapy, and 59% received definitive radiotherapy; 41% of patients also received concurrent chemotherapy. Chemotherapy per arm: Aloe arm: 36% Placebo arm: 47%  +
T
Major abdominal surgery for mainly hepatocellular cancer and gastric cancer in the 24 hours  +
U
Preoperative and postoperative chemotherapy was administered to patients with stage II and III esophageal cancer; postoperative chemotherapy was administered to patients with stage II and III gastric cancer and all patients with stage III colorectal cancer; Local radiation or molecular-targeting therapy was combined with chemotherapy for selected patients with relapse  +
V
3.4% of patients received chemotherapy in addition to local treatment Time between radiotherapy/surgery and randomization (month) - vit. A group: < 2: 51%; 2-12: 32%, > 12: 17% - NAC group: < 2: 52%; 2-12: 30%, > 12: 17%, missing: 1% - vit. A and NAC group: < 2: 49%; 2-12: 36%, > 12: 15% - control group: < 2: 49%; 2-12: 34%, > 12: 17%  +